Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection

• Status: Terminated
• Trial end date: 2021-04-19
• Target enrollment: 0
• Participant gender: All

Summary

This study is a phase II, parallel, prospective, randomized, double-blind, placebo controlled trial. The present study will aim to address the efficacy and safety of acute administration of triiodothyronine on ICU patients diagnosed with pulmonary infection due to COVID-19 and require mechanical respiratory support or ECMO.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.
• Collaborators: Attikon Hospital; ATTIKON University Hospital

Criteria

Inclusion Criteria:

• Patients diagnosed with pulmonary infection due to COVID-19, admitted in ICU and require mechanical ventilation or ECMO

• Male and female with Age>18 years old

• Signed informed consent from patient or relatives

Exclusion Criteria:

• Pregnant or breast-feeding women

• Severe systemic disease (cancer, auto-immune etc) before infection accompanied by reduced life expectancy <6 months

• Participation in another trial of an investigational drug or device

• Corticosteroid Use before initiation of treatment

• Sympathomimetic Use before initiation of treatment (epinephrine, norepinephrine, dobutamine, dopamine, phenylephrine)